299 related articles for article (PubMed ID: 29888434)
1. Targeting tryptophan availability to tumors: the answer to immune escape?
Badawy AA
Immunol Cell Biol; 2018 Nov; 96(10):1026-1034. PubMed ID: 29888434
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan metabolism and disposition in cancer biology and immunotherapy.
Badawy AA
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36286592
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements.
Badawy AA
Neuropharmacology; 2017 Jan; 112(Pt B):248-263. PubMed ID: 26617070
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
Front Immunol; 2020; 11():55. PubMed ID: 32117235
[TBL] [Abstract][Full Text] [Related]
6. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
7. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
8. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
10. The end of the road for the tryptophan depletion concept in pregnancy and infection.
Badawy AA; Namboodiri AM; Moffett JR
Clin Sci (Lond); 2016 Aug; 130(15):1327-33. PubMed ID: 27358028
[TBL] [Abstract][Full Text] [Related]
11. Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives.
Peyraud F; Guegan JP; Bodet D; Cousin S; Bessede A; Italiano A
Front Immunol; 2022; 13():807271. PubMed ID: 35173722
[TBL] [Abstract][Full Text] [Related]
12. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression.
Crump LS; Floyd JL; Kuo LW; Post MD; Bickerdike M; O'Neill K; Sompel K; Jordan KR; Corr BR; Marjon N; Woodruff ER; Richer JK; Bitler BG
Cancer Res Commun; 2024 Mar; 4(3):822-833. PubMed ID: 38451784
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan metabolism, disposition and utilization in pregnancy.
Badawy AA
Biosci Rep; 2015 Sep; 35(5):. PubMed ID: 26381576
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of targeting tryptophan catabolism in cancer.
Opitz CA; Somarribas Patterson LF; Mohapatra SR; Dewi DL; Sadik A; Platten M; Trump S
Br J Cancer; 2020 Jan; 122(1):30-44. PubMed ID: 31819194
[TBL] [Abstract][Full Text] [Related]
16. Hypothesis: Metabolic targeting of 5-aminolevulinate synthase by tryptophan and inhibitors of heme utilisation by tryptophan 2,3-dioxygenase as potential therapies of acute hepatic porphyrias.
Badawy AA
Med Hypotheses; 2019 Oct; 131():109314. PubMed ID: 31443750
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors.
Schramme F; Crosignani S; Frederix K; Hoffmann D; Pilotte L; Stroobant V; Preillon J; Driessens G; Van den Eynde BJ
Cancer Immunol Res; 2020 Jan; 8(1):32-45. PubMed ID: 31806638
[TBL] [Abstract][Full Text] [Related]
18. Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism.
Trézéguet V; Fatrouni H; Merched AJ
Cells; 2021 Dec; 10(12):. PubMed ID: 34943977
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
20. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
